PRPO Precipio (PRPO) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001043961
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter
What the filings say about PRPO
Insiders, 180 days
-$100.3K net sold
1 seller · 0% of sales under a 10b5-1 plan
Precipio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Precipio, Inc. insiders sold a net $100.3K of stock across 35 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 16 earlier Form 4 trades (code P or S) here by this insider (11 buys, 5 sales), the last on May 20, 2026.
- +44.4% median (+39.5% mean) 90-day return after 9 previous buys.
- The trade is 30.0% of the 3,000 shares held after it.
- No other insider sold within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SANDBERG RICHARD A sold about $22.5K of PRPO on May 21, 2026; 8 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (11 buys, 3 sales), the last on May 19, 2026.
- +44.4% median (+39.5% mean) 90-day return after 9 previous buys.
- The trade is 25.0% of the 8,142 shares held after it.
- No other insider sold within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SANDBERG RICHARD A sold about $50.6K of PRPO on May 20, 2026; 8 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (11 buys, 3 sales), the last on May 19, 2026.
- +44.4% median (+39.5% mean) 90-day return after 9 previous buys.
- The trade is 12.8% of the 3,900 shares held after it.
- No other insider sold within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SANDBERG RICHARD A sold about $12.5K of PRPO on May 20, 2026; 8 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (11 buys, 2 sales), the last on May 30, 2025.
- +44.4% median (+39.5% mean) 90-day return after 9 previous buys.
- The trade is 13.6% of the 4,400 shares held after it.
- No other insider sold within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SANDBERG RICHARD A sold about $14.7K of PRPO on May 19, 2026; 8 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Jan 2, 2026.
- +6.6% median (+4.4% mean) 90-day return after 9 previous buys.
- The trade is 1.8% of the 1,034 shares held after it.
- No other insider bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Sabet Ahmed Zaki bought about $531 of PRPO on Apr 1, 2026; 8 funds added in the latest 13F quarter.35 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$100.3K over 180 days
more than 55% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 88% of Medical Devices
Revenue
+30.5% year over year
more than 79% of Medical Devices
Margin
-1.5% net margin
more than 66% of Medical Devices
Buybacks
$29.0K repurchased, FY to 2026-06-30
the lowest in Medical Devices
Short interest
4.9% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 54% of Medical Devices
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch PRPO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-5.0%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PRPO: institutional holders (13F)
13F holdings, latest reported quarter
46,148 sh
$1.1M
34,655 sh
$858.1K
18,691 sh
$462.9K
16,199 sh
$401.1K
14,714 sh
$364.3K
Congress trades in PRPO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PRPO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PRPO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$133.4K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$8.8K position · as of 2026-06-30
0.0%
Dimensional US Sustainability Core 1 ETF
$21.8K position · as of 2026-07-31
0.0%
U.S. MICRO CAP PORTFOLIO
$56.6K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$438.1K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$183.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $100.3K sold by insiders over 180 days, 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PRPO financials
Revenue growth
+30.5%
XBRL, annual
Net margin
-1.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$60.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PRPO
| FY Dec 2025 | $53.5M |
| FY Dec 2024 | $41.8M |
| FY Dec 2023 | $29.5M |
| FY Dec 2022 | $20.3M |
| FY Dec 2021 | $17.7M |
| Jun 2026 | $15.0M |
| Mar 2026 | $15.4M |
| Dec 2025 | $15.3M |
| Sep 2025 | $15.2M |
| Jun 2025 | $12.3M |
| Mar 2025 | $10.7M |
| Dec 2024 | $12.0M |
| Sep 2024 | $11.9M |
At each fiscal year end
Single quarter
Net margin, TTM
-2.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PRPO
| FY Dec 2025 | -0.7% |
| FY Dec 2024 | -10.3% |
| FY Dec 2023 | -19.8% |
| FY Dec 2022 | -60.0% |
| FY Dec 2021 | -48.2% |
| Jun 2026 | -1.5% |
| Mar 2026 | -9.4% |
| Dec 2025 | +3.4% |
| Sep 2025 | -0.5% |
| Jun 2025 | +0.6% |
| Mar 2025 | -8.2% |
| Dec 2024 | -3.0% |
| Sep 2024 | -5.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$789.0K
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PRPO
| FY Dec 2025 | $359.0K |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$3.7M |
| FY Dec 2022 | -$8.0M |
| FY Dec 2021 | -$7.3M |
| Jun 2026 | $528.0K |
| Mar 2026 | $14.0K |
| Dec 2025 | $291.0K |
| Sep 2025 | -$44.0K |
| Jun 2025 | $294.0K |
| Mar 2025 | -$182.0K |
| Dec 2024 | $521.0K |
| Sep 2024 | -$68.0K |
At each fiscal year end
Single quarter
Debt to equity
0.02x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity PRPO
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.02x |
| FY Dec 2022 | 0.02x |
| FY Dec 2021 | 0.01x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.01x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
3.38x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt PRPO
| FY Dec 2025 | 8.90x |
| FY Dec 2024 | 1.17x |
| FY Dec 2023 | -10.44x |
| FY Dec 2022 | -19.85x |
| FY Dec 2021 | -35.36x |
| Jun 2026 | 3.38x |
| Mar 2026 | 11.33x |
| Dec 2025 | 8.90x |
| Sep 2025 | 10.40x |
| Jun 2025 | 10.05x |
| Mar 2025 | 4.89x |
| Dec 2024 | 1.17x |
| Sep 2024 | -0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-9.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PRPO
| FY Dec 2025 | -2.7% |
| FY Dec 2024 | -32.3% |
| FY Dec 2023 | -38.1% |
| FY Dec 2022 | -59.6% |
| FY Dec 2021 | -44.0% |
| Jun 2026 | -9.0% |
| Mar 2026 | -7.1% |
| Dec 2025 | -2.7% |
| Sep 2025 | -9.8% |
| Jun 2025 | -14.8% |
| Mar 2025 | -25.3% |
| Dec 2024 | -32.3% |
| Sep 2024 | -24.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-6.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PRPO
| FY Dec 2025 | -1.9% |
| FY Dec 2024 | -24.4% |
| FY Dec 2023 | -29.6% |
| FY Dec 2022 | -46.9% |
| FY Dec 2021 | -33.3% |
| Jun 2026 | -6.1% |
| Mar 2026 | -4.8% |
| Dec 2025 | -1.9% |
| Sep 2025 | -6.6% |
| Jun 2025 | -10.0% |
| Mar 2025 | -18.0% |
| Dec 2024 | -24.4% |
| Sep 2024 | -16.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital PRPO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-9.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PRPO
| FY Dec 2025 | -7.9% |
| FY Dec 2024 | -30.5% |
| FY Dec 2023 | -47.5% |
| FY Dec 2022 | -59.0% |
| FY Dec 2021 | -45.5% |
| Jun 2026 | -9.6% |
| Mar 2026 | -11.6% |
| Dec 2025 | -7.9% |
| Sep 2025 | -14.3% |
| Jun 2025 | -19.2% |
| Mar 2025 | -22.4% |
| Dec 2024 | -30.5% |
| Sep 2024 | -36.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PRPO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$33.1M
market value at close 2026-10-23 on 2026-08-10 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value PRPO
| FY Dec 2025 | $37.7M |
| FY Dec 2024 | $7.2M |
| FY Dec 2023 | $8.1M |
| FY Dec 2022 | $248.4M |
| FY Dec 2021 | $706.1M |
| Jun 2026 | $41.5M |
| Mar 2026 | $42.1M |
| Dec 2025 | $37.7M |
| Sep 2025 | $26.6M |
| Jun 2025 | $15.7M |
| Mar 2025 | $8.6M |
| Dec 2024 | $7.2M |
| Sep 2024 | $9.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.2%
TTM free cash flow over market value at close 2026-10-23
FCF yield PRPO
| FY Dec 2025 | +0.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -39.9% |
| FY Dec 2022 | -3.2% |
| FY Dec 2021 | -1.0% |
| Jun 2026 | +1.8% |
| Mar 2026 | +1.2% |
| Dec 2025 | +0.9% |
| Sep 2025 | +2.0% |
| Jun 2025 | +3.4% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PRPO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $53.5M | $41.8M | $29.5M | $20.3M |
| Gross profit | $10.7M | $7.6M | $6.0M | $2.5M |
| Operating income | -$1.2M | -$4.2M | -$7.6M | -$12.8M |
| Net income | -$363.0K | -$4.3M | -$5.9M | -$12.2M |
| EPS (diluted) | -0.23 | -2.93 | -4.51 | -10.73 |
| Operating cash flow | $685.0K | $439.0K | -$3.6M | -$7.7M |
| Cash | $2.7M | $1.4M | $1.5M | $3.4M |
| Long-term debt | $47.0K | $77.0K | $106.0K | $134.0K |
SEC XBRL, fiscal years, as known on 2026-10-27
PRPO Stock Sonar score 6/7 axes
Find similar shapesComparePRPO ranks highest on financial health (89th percentile) and growth (79th), and lowest on institutional and government (12th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PRPO filings, in plain words
Are Precipio insiders buying or selling PRPO?
In the 180 days to 2026-10-27, Precipio insiders were net sellers, a net $100.3K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-27, Precipio insiders were net sellers of PRPO, a net $100.3K across purchases and sales reported on Form 4 by 1 seller. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
